Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Loss of ARID1A 'loops' in STING.

Trends in immunology - 1 Aug 2024

Goswami Sangeeta, Sharma Padmanee

Abstract excerpt

In a recent article, Maxwell et al. report that loss of tumor cell-specific AT-rich interaction domain 1A (ARID1A), a component of the chromatin remodeling SWI/SNF complex, triggers antitumor immunity via R-loop-mediated upregulation of the type-I interferon (IFN) pathway. These recent findings uncover a molecular mechanism underlying improved responses to immune checkpoint therapy (ICT) seen in patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromatin Assembly and Disassembly
Share to DNA-Binding Proteins
Share to Interferon Type I

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Membrane Proteins

Share to Mutation

Share to Neoplasms

Share to Signal Transduction

Share to Transcription Factors

Source

Identifiers

PMID: 39060141
DOI: 10.1016/j.it.2024.07.001

Genes

ARID1A

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Loss of ARID1A 'loops' in STING.PMID 39060141Read ↗

ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity.Semantic proximity Read ↗

Mutant ARID1A: igniting cancer immunotherapy.Semantic proximity Read ↗

ARID1A regulates DNA repair through chromatin organization and its deficiency triggers DNA damage-mediated anti-tumor immune responseSemantic proximity Read ↗

Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy.Semantic proximity Read ↗

ARID1A deficiency and immune checkpoint blockade therapy: From mechanisms to clinical applicationSemantic proximity Read ↗

ARID1B Deficiency Leads to Impaired DNA Damage Response and Activated cGAS-STING Pathway in Non-Small Cell Lung CancerSemantic proximity Read ↗

ARID1B Deficiency Leads to Impaired DNA Damage Response and Activated cGAS- STING Pathway in Non-Small Cell Lung CancerSemantic proximity Read ↗

Inhibition of the ATM/Chk2 axis promotes cGAS/STING signaling in ARID1A-deficient tumorsSemantic proximity Read ↗

Effect and biomarker of immune checkpoint blockade therapy for ARID1A deficiency cancersSemantic proximity Read ↗

Chromatin Remodelers Are Regulators of the Tumor Immune MicroenvironmentSemantic proximity Read ↗

ARID1A and Its Impact Across the Hallmarks of CancerSemantic proximity Read ↗

ARID1A loss in cancer: Towards a mechanistic understanding.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.